Uvea (Choroid, Ciliary Body, Iris)

C69.3-C69.4WHO — Eye Tumours

Eye & Orbit

Prognosis

This section is being prepared by our editorial process.

🔬 Histological Types

📚 Latest Research

2026-09-09

[Analysis of therapeutic effects of proton and heavy ion radiotherapy on uveal melanoma].

Yue H, et al

A retrospective study of 69 patients with uveal melanoma treated at Fudan University between 2015 and 2025 found that both proton beam therapy (12 patients, 17.4%) and heavy ion radiotherapy (57 patients, 82.6%) produced statistically significant tumor regression: the largest basal tumor diameter decreased from 11.3±2.9 mm to 9.5±3.5 mm and tumor thickness fell from 6.7±2.3 mm to 5.5±2.7 mm (both P<0.05). The eye preservation rate was high, with only 4 patients (5.8%) ultimately requiring enucleation, while 19 patients retained best-corrected visual acuity of ≥0.1 after treatment. The most common complications were radiation-induced retinopathy (42.0%), macular edema (37.7%), retinal detachment (34.8%), and cataracts (33.3%), a profile consistent with published particle-therapy benchmarks. These findings support particle radiotherapy — particularly heavy ion therapy — as an effective organ-preserving treatment for uveal melanoma in a Chinese clinical setting.

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology

Source →

2026-09-07

Key barriers in utilizing advanced T-cell engager strategies on solid tumors.

Ku BM, et al

A comprehensive review identifies the key biological and immunological barriers preventing T-cell engager (TCE) therapies from achieving in solid tumors the success already seen in blood cancers, while highlighting that the recent approvals of tebentafusp for uveal melanoma and tarlatamab for small cell lung cancer mark a turning point for the field. The authors detail how solid tumors resist TCEs through antigen scarcity, physical and biochemical obstacles to T-cell infiltration, immunosuppressive microenvironments, and both primary and acquired resistance mechanisms. Next-generation strategies — including re-engineered antibody formats, rational combination regimens, and biomarker-guided patient selection — are presented as the most promising routes to broader clinical benefit. The expert opinion concludes that integrating logical target selection, advanced engineering, and deliberate clinical trial design will allow TCEs to meaningfully expand the reach of modern immunotherapy into solid tumors.

Expert review of anticancer therapy

Source →

2026-09-03

Retinal pigment epithelial carcinoma masquerading as choroidal melanoma-A rare case report.

Das BC, et al

A 63-year-old woman presenting with progressive visual loss and intermittent throbbing pain in her right eye was ultimately diagnosed with retinal pigment epithelial (RPE) adenocarcinoma, an exceedingly rare intraocular malignancy that had been clinically mistaken for choroidal melanoma. Histopathological examination revealed an infiltrative epithelial neoplasm with ill-defined glandular differentiation and moderate cytological atypia, while immunohistochemical staining with epithelial membrane antigen, cytokeratin 7, HMB-45, and S-100 confirmed the RPE origin of the lesion. This case underscores that RPE adenocarcinoma must be included in the differential diagnosis of pigmented intraocular tumors, and that combined histopathology and immunohistochemistry are essential for accurate diagnosis to avoid misclassification as the far more common choroidal melanoma.

Indian journal of pathology & microbiology

Source →